Eris Lifesciences to fully acquire Swiss Parenterals for INR 4.23bn

Eris Lifesciences Limited's board of directors approved the acquisition of the remaining 30% of Swiss Parenterals Limited's share capital, making Swiss Parenterals a wholly-owned subsidiary. The total purchase consideration for this stake is INR 4,23,30,00,000, which will be discharged by issuing up to 23,06,372 new equity shares of Eris Lifesciences on a preferential basis to Naishadh Shah, a director of Swiss Parenterals Limited. The acquisition aims to enhance operational synergy, strengthen long-term strategic presence, and improve cost efficiencies.

The equity shares will be issued at a price of INR 1,835.35 per share, determined by a valuation report dated November 24, 2025. This transaction, categorized as a related party transaction, is expected to complete prior to March 31, 2026. Shareholders' consent will be sought via postal ballot for the issuance of shares and the material related party transaction. The cut-off date for e-voting eligibility is November 21, 2025. Swiss Parenterals Limited, incorporated on February 4, 1997, reported turnovers of INR 220.80 crores in FY 2022-23, INR 282.97 crores in FY 2023-24, and INR 351.11 crores in FY 2024-25.